Patents by Inventor Sabina Pecchi
Sabina Pecchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110052578Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.Type: ApplicationFiled: August 24, 2010Publication date: March 3, 2011Inventors: Abran Q. Costales, Shenlin Huang, Jeff (Xianming) Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
-
Patent number: 7855295Abstract: Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.Type: GrantFiled: January 24, 2005Date of Patent: December 21, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Weibo Wang, Zhi-Jie Ni, Paul Barsanti, Sabina Pecchi, Yi Xia, Nathan Brammeier, Megan C. Phillips, Eliza Jazan, Kelly Wayman, David Dibble, Jie-Kai Cheng
-
Publication number: 20100249126Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: ApplicationFiled: January 22, 2007Publication date: September 30, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel J. Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Meritt, Charles Voliva, Marion Wiesmann, Xiahua Xin
-
Patent number: 7767669Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: August 8, 2008Date of Patent: August 3, 2010Assignee: Novartis AGInventors: John M. Nuss, Sabina Pecchi, Paul A. Renhowe
-
Publication number: 20100184754Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: January 4, 2010Publication date: July 22, 2010Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, JR., Christopher McBride, Elisa Jazan
-
Publication number: 20100075965Abstract: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.Type: ApplicationFiled: February 14, 2007Publication date: March 25, 2010Inventors: Zhi-Jie Ni, Sabina Pecchi, Matthew Burger, Wooseok Han, Aaron Smith, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Joelle Verhagen, Yanchen Zhang, Ed Iwanowicz, Tom Hendrickson, Mark Knapp, Hanne Merritt, Charles Voliva, Marion Wiesmann, Darren Mark Legrand, Ian Bruce, James Dale, Jiong Lan, Barry Levine, Abran Costales, Jui Liu, Teresa Pick, Daniel Menezes
-
Publication number: 20100048547Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.Type: ApplicationFiled: February 6, 2008Publication date: February 25, 2010Inventors: Gordana Atallah, Sarah Bartulis, Matthew Burger, Hanne Merritt, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Aaron Smith, Charles Voliva, Allan Wagman, Yanchen Zhang
-
Publication number: 20090281100Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.Type: ApplicationFiled: December 23, 2008Publication date: November 12, 2009Inventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Machajewski, Christopher McBride, William R. McCrea, JR., Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann, Kelly Wayman
-
Publication number: 20090258016Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.Type: ApplicationFiled: June 5, 2009Publication date: October 15, 2009Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
-
Patent number: 7598268Abstract: Organic compounds having the formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: July 8, 2004Date of Patent: October 6, 2009Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Christopher McBride, Elisa Jazan
-
Patent number: 7576221Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.Type: GrantFiled: June 20, 2005Date of Patent: August 18, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
-
Publication number: 20090060912Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: August 8, 2008Publication date: March 5, 2009Applicant: CHIRON CORPORATIONInventors: John N. Nuss, Sabina Pecchi, Paul A. Renhowe
-
Patent number: 7470709Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.Type: GrantFiled: August 19, 2003Date of Patent: December 30, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Machajewski, Christopher McBride, William R. McCrea, Jr., Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann, Kelly Wayman
-
Patent number: 7423148Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: November 21, 2003Date of Patent: September 9, 2008Assignee: Chiron CorporationInventors: John N. Nuss, Sabina Pecchi, Paul A. Renhowe
-
Patent number: 7368459Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: GrantFiled: October 11, 2006Date of Patent: May 6, 2008Assignee: Chiron CorporationInventors: Paul A. Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Wernette Hammond, Sabina Pecchi
-
Publication number: 20080070906Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: October 2, 2007Publication date: March 20, 2008Inventors: Paul Renhowe, Sabina Pecchi, Timothy Machajewski, Cynthia Shafer, Clarke Taylor, William McCrea, Christopher McBride, Elisa Jazan
-
Patent number: 7335774Abstract: A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.Type: GrantFiled: March 29, 2005Date of Patent: February 26, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Paul A. Renhowe, Cynthia M. Shafer, Timothy D. Machajewski, Sabina Pecchi, Christopher McBride
-
Patent number: 7326711Abstract: Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.Type: GrantFiled: June 17, 2004Date of Patent: February 5, 2008Assignee: Chiron CorporationInventors: Weibo Wang, Ryan N. Constantine, Liana Marie Lagniton, Sabina Pecchi, Matthew T. Burger, Manoj C. Desai
-
Publication number: 20070032528Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 11, 2006Publication date: February 8, 2007Inventors: Paul Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Hammond, Sabina Pecchi
-
Patent number: 7138409Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: GrantFiled: April 14, 2004Date of Patent: November 21, 2006Assignee: Chiron CorporationInventors: Paul A. Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Wernette Hammond, Sabina Pecchi